Table 1.

Overview of LSD1/KDM1A inhibitors in clinical trials

Drugs	Phase	Trial number	Diseases	Status
ORY-1001	Phase I/II	NA*	AML	Unknown
	Phase I	NCT02913443	SCLC	Completed
	Preclinical	NA*	AML, solid tumors	Unknown
TCP	Phase I	NCT02273102	AML; MDS	Active, not recruiting
	Phase I/II	NCT02261779	Relapsed/refractory AML	Unknown
	Phase I/II	NCT02717884	Non-M3 AML blasts	Recruiting
GSK2879552	Phase I	NCT02034123	Relapsed/refractory SCLC	Terminated
		NCT02177812	AML	Terminated
	Phase II	NCT02929498	High-risk MDS	Terminated
INCB059872	Phase I/II	NCT02712905	Solid tumors and hematologic malignancy	Recruiting
	Phase I	NCT03514407	Relapsed Ewing sarcoma	Recruiting
	Phase I/II	NCT02959437	Solid tumors Advanced malignancies Metastatic cancer	Active, not recruiting
	Phase I	NCT03132324	Sickle cell disease	Terminated
	Phase I/II	NCT04061421	MDS/MPN	Not yet recruiting
IMG-7289	Phase II	NCT03136185	Myelofibrosis	Recruiting
	Phase II	NCT04081220	Essential thrombocythemia	Not yet recruiting
	Phase I	NCT02842827	AML and MDS	Completed
CC-90011	Phase I	NCT02875223	Relapsed/refractory solid tumors and non-Hodgkin’s lymphomas	Recruiting
	Phase I/II	NCT03850067	SCLC	Recruiting
ORY-2001	Phase I	NA*	Multiple sclerosis	Recruiting
	Phase IIa	NCT03867253	Mild to moderate Alzheimer’s disease	Recruiting

*NA means the related data are not available on the ClinicalTrials.gov website and excerpted from the Oryzon Genomics website. Updated on October 1, 2019